Latest Breaking News On - Allakos analyst turns bullish - Page 1 : vimarsana.com

Allakos reports disappointing topline data from phase 2 trials for lirentelimab in atopic dermatitis and chronic spontaneous urticaria. Company undergoes restructuring to focus on AK006, extending cash runway into mid-2026.

Allakos incCraig patersonUrticaria activity scoreChief medical officerAllakos analyst turns bullishSignificant upside if study results areAfter disappointing data